Skip to main content

epigenomics-logo

Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s lead product, Epi proColon® , the first and only FDA-approved blood-based colorectal cancer screening test.

{iframe}http://www.epigenomics.com/uploads/media/approval_pm_eng.pdf{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.